Thursday, May 3 - Dinner Short Course, 5:45pm – 8:15pm

SC10: Critical Considerations for the Design and Development of Antibody-Drug Conjugates

Instructors:
Isabel Figueroa, Ph.D., Scientist, PTPK, Genentech, Inc.
Shawn Owen, Ph.D., Assistant Professor, Pharmaceutical Chemistry, University of Utah

Objectives:

Antibody Drug Conjugates are increasingly employed as novel targeted therapies. They consist of an antibody, a linker and a payload. ADC can combine the exquisite selectivity of antibodies with the therapeutic activity of small molecule drugs to achieve the desired therapeutic objectives. Achieving the desired therapeutic outcome, when using an ADC candidate, will depend on attributes related to the target, antibody, linker, and the payload. In this course, we have attempted to evaluate some of the key topics important for design and development of this class of therapeutics:

Course Outline:

• Introduction
• Considerations for Design and Selection of ADCs
  Isabel Figueroa, Ph.D., Scientist, PTPK, Genentech, Inc.
• Design and Selection of Linker, Payload and Conjugation Chemistry
  Shawn Owen, Ph.D., Assistant Professor, Pharmaceutical Chemistry, University of Utah

Instructor Bios:

Isabel Figueroa, Ph.D., Scientist, PTPK, Genentech, Inc.

After completing her Ph.D. in Chemical Engineering, Isabel joined the Chemical Process Development Department at Eli Lilly and Company where her focus was to introduce the use quantitative methods into multidisciplinary teams to support decision making in through different stages of the drug development process. Now, at Merck Research Laboratories, she is responsible for the quantitative design and evaluation of diverse novel therapeutic modalities and for providing science-based strategies to inform first-in-human dosing. Her expertize reside on mechanistic understanding preclinical pharmacology and the design and execution of drug translational strategies. Dr. Figueroa is interested in general applications of systems pharmacology and the use of quantitative principles to enable the discovery of new therapeutics.

Shawn Owen, Ph.D., Assistant Professor, Pharmaceutical Chemistry, University of Utah

Shawn C. Owen, Ph.D is an Assistant Professor in Pharmaceutics and Pharmaceutical Chemistry and Adjunct Professor of Internal Medicine, Bioengineering, and Medicinal Chemistry at the University of Utah. He is also a member of the Huntsman Cancer Institute Experimental Therapeutics Program and the Nano-Institute of Utah.Current research in his lab focuses on evaluating the pharmaceutic stability of antibody-based therapeutics, creating ADCs that induce self-amplifying therapeutic cascades, and engineering antibody-split enzyme systems for diagnostic applications.